Seattle Genetics

Seattle Genetics, co-founded by Clay Siegall, is a biotechnology company leading the field of antibody-drug conjugates (ADCs) for the treatment of cancer. Our technology is designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. Our lead program, ADCETRIS® (brentuximab vedotin), is the first in a new class of ADCs and, in collaboration with Takeda Pharmaceutical Company Limited, is approved in more than 55 countries. To expand on the ADCETRIS opportunity, we are conducting a broad clinical development program to evaluate its therapeutic potential in a range of other lymphoma and non-lymphoma settings. Seattle Genetics is also advancing a robust pipeline of clinical-stage programs, including SGN-CD19A, SGN-CD33A, SGN-LIV1A, SGN-CD70A, ASG-22ME, ASG-15ME and SEA-CD40. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including AbbVie, Agensys (an affiliate of Astellas), Bayer, Genentech, GlaxoSmithKline and Pfizer. Across both internal and collaborator programs, there are more than 20 ADCs in clinical development using our proprietary approach to empowering antibodies.
Company Growth (employees)
Type
Public
HQ
Bothell, US
Founded
1998
Size (employees)
890 (est)+18%
Seattle Genetics was founded in 1998 and is headquartered in Bothell, US

Key People at Seattle Genetics

Clay B. Siegall

Clay B. Siegall

Co-founder, President , CEO & Chairman
Todd E. Simpson

Todd E. Simpson

CFO
Eric Dobmeier

Eric Dobmeier

Chief Operating Officer
Vaughn Himes

Vaughn Himes

EVP, Process Sciences and Technical Operations
Chris Boerner

Chris Boerner

Executive Vice President, Commercial
Jonathan Drachman

Jonathan Drachman

Chief Medical Officer; EVP, Research and Development

Seattle Genetics Office Locations

Seattle Genetics has offices in Bothell and Washington
Bothell, US (HQ)
21717 30th Dr Se

Seattle Genetics Data and Metrics

Seattle Genetics Financial Metrics

Seattle Genetics's revenue was reported to be $418.1 m in FY, 2016 which is a 24% increase from the previous period.
Numbers are in $, USD

Revenue (FY, 2016)

418.1 m

Revenue growth (FY, 2015 - FY, 2016), %

24%

Gross profit (FY, 2016)

390 m

Gross profit margin (FY, 2016), %

93%

Net income (FY, 2016)

(140.1 m)

EBIT (FY, 2016)

(142.7 m)

Market capitalization (24-May-2017)

9.6 b

Closing share price (24-May-2017)

66.7

Cash (31-Dec-2016)

108.7 m
Seattle Genetics's current market capitalization is $9.6 b.
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

269.3 m286.8 m336.8 m418.1 m

Revenue growth, %

6%17%24%

Cost of goods sold

13.8 m17.5 m24.5 m28.2 m

Gross profit

255.5 m269.2 m312.3 m390 m

Gross profit Margin, %

95%94%93%93%

Operating expense total

318.4 m346.6 m433.3 m560.9 m

EBIT

(62.9 m)(77.4 m)(121 m)(142.7 m)

EBIT margin, %

(23%)(27%)(36%)(34%)

Net Income

(62.5 m)(76.1 m)(120.5 m)(140.1 m)
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

64.1 m56.9 m102.3 m108.7 m

Accounts Receivable

29.5 m39.2 m52.9 m61.9 m

Inventories

27.1 m43.5 m57 m68.1 m

Current Assets

437.3 m408 m771.1 m734.6 m

PP&E

40.8 m46.1 m49.6 m62.9 m

Total Assets

483.9 m459 m895.1 m838.4 m

Accounts Payable

Current Liabilities

99.2 m125.9 m134.3 m148.5 m

Non-Current Liabilities

154.5 m122.2 m74.9 m55.8 m

Total Liabilities

253.7 m248.1 m209.2 m204.3 m

Additional Paid-in Capital

960.4 m1 b1.6 b1.7 b

Retained Earnings

(730.3 m)(806.4 m)(926.9 m)(1.1 b)

Total Equity

230.2 m210.8 m685.9 m634.1 m

Financial Leverage

2.1 x2.2 x1.3 x1.3 x
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(62.5 m)(76.1 m)(120.5 m)(140.1 m)

Depreciation and Amortization

8.6 m12.5 m14.5 m18 m

Accounts Receivable

3.9 m(9.7 m)(14 m)(9 m)

Inventories

10.7 m(16 m)(14 m)(11 m)

Accounts Payable

Cash From Operating Activities

(1.1 m)(60 m)(133.2 m)(97 m)

Purchases of PP&E

(22.2 m)(17.2 m)(13.4 m)(27.8 m)

Cash From Investing Activities

(24.6 m)36.6 m(375.9 m)68.2 m

Cash From Financing Activities

35.2 m16.2 m554.4 m35.2 m
Y, 2016

Financial Leverage

1.3 x

Seattle Genetics Market Value History

Seattle Genetics Median Salaries

Source: 47 public H-1B filings from Seattle Genetics

Seattle Genetics Online and Social Media Presence

Seattle Genetics News and Updates

Seattle Genetics Company Life and Culture

You may also be interested in